Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16418171 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Weigert C, et al. (2006) Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281, 7060-7 16418171
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S307-p - IRS1 (mouse)
Orthologous residues
IRS1 (human): S312‑p, IRS1 (mouse): S307‑p, IRS1 (rat): S307‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', C2C12 (myoblast), L6 (myoblast), liver, myoblast
 Cellular systems studied:  cell lines, primary cells, tissue
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 no change compared to control Muscle
IL-6 increase Liver

S318-p - IRS1 (mouse)
Orthologous residues
IRS1 (human): S323‑p, IRS1 (mouse): S318‑p, IRS1 (rat): S318‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', C2C12 (myoblast), L6 (myoblast), liver, myoblast
 Cellular systems studied:  cell lines, primary cells, tissue
 Species studied:  human, mouse, rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCD (mouse) siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, phospho-antibody, co-immunoprecipitation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase Muscle, C2C12, L6, 1' human myotubes
IL-6 no change compared to control Liver
PKCD (human) increase C2C12 cells
siRNA decrease PKC delta siRNA
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Comments:  Phosphorylation of S318 leads to an increase of phospho-Ser473 Akt1 in L6GLUT4 myotubes.

Y705-p - STAT3 (mouse)
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', C2C12 (myoblast), L6 (myoblast), liver, myoblast
 Cellular systems studied:  cell lines, primary cells, tissue
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-6 increase Liver, muscle, C2C12, L6, 1' human myotubes


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.